Re: My previous response (Trial of ivermectin for treatment and prophylaxis of COVID-19) in response to Chloroquine and hydroxychloroquine in covid-19
We regret any inference that the intended dose of Ivermectin in potential controlled trials of post-exposure prophylaxis for COVI-19 should try to emulate the high concentrations that were virocidal in the in-vitro studies. Our intent was to promote consideration of Ivermectin doses known to be easily and safely administered, such as used for scabies treatment or control. This was clearly stated in an earlier response we wrote on the same topic (https://www.bmj.com/content/369/bmj.m1432/rr-26). We hope that no harm has been done by misguided administrations caused by our communication.
Competing interests: No competing interests